Interesting to select bothThe success of OSL will be the failure...

Interesting to select both

The success of OSL will be the failure of Sirtex

I used to follow this development in the mid 2000s under psvida and was looking at the 2005 psvida annual report.

They were looking a lot more then at liver cancers as well - but it seems to be off the agenda at the moment. I am sure they (OSL) will get back in to that.

The patent is also worth looking at:

(75) Inventors: Roger ASTON, Malvern (GB); A61K 39/395 (200601)

(73) Assignee: pSiMedica Limited, Malvern (GB) A61K 31/695 (2006.01)

(22) Filed. . Dec . 8 , 2011

[0002] This invention relates to devices and methods for
treatment of cancer, including liver cancer, kidney cancer,
prostate cancer, brain cancer, and breast cancer. More speci
cally the invention relates to devices and methods or the
treatment of liver cancer.

and

[0050] The anti-cancer component may comprise a radio nucleotide, and the radionucleotide may be selected from one
or more of: 90Y, 32F, 124Sb, 114In, 59Fe, 76As, 140La, 47Ca,
103Pd’ 8981,’ r311’ r251’ 6OCO’ 19211,’ 1213’ 71Ge’ 64Cu’ 203Pb and l98‘Axu

Sirtex uses Yittrium 90